Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Johnson & Johnson (NY:JNJ)

193.99 +0.77 (+0.40%)
Streaming Delayed Price Updated: 1:57 PM EDT, Oct 20, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Johnson & Johnson

< Previous 1 2
...
19 20 21 22 23 24 25 26 27
...
99 100 Next >
Can Biotech Stocks Survive The Precarious Macro?
We were having a nice rally in January 2025 until the reality of tariffs hit on Friday which killed the momentum developing off the mid-January lows. 
Via Talk Markets
Topics Stocks / Equities World Trade
Teva Pharma: Why This Generic Drug Giant Is a Smart Buy Now
Teva Pharmaceuticals is the world's largest generic drug maker with over 500 generics in its portfolio, but shares sold off on its recent earnings, buying opp? 
Via MarketBeat
Is Johnson & Johnson Stock a Buy?
Via The Motley Fool
Johnson & Johnson Announces a Major Acquisition. Can It Turn the Stock's Fortunes Around?
Via The Motley Fool
Did Johnson & Johnson Just Give Investors 23 Billion Reasons to Buy Its Stock?
Via The Motley Fool
Johnson & Johnson's Options Frenzy: What You Need to Know
 
Via Benzinga
Where Johnson & Johnson Stands With Analysts
 
Via Benzinga
The Dogs Of The Dow 2025
The Dogs of the Dow is an investing strategy well-known to retail and institutional investors. 
Via Talk Markets
Topics Stocks Stocks / Equities
Johnson & Johnson (NYSE:JNJ) Posts Q4 Sales In Line With Estimates
Multinational healthcare company Johnson & Johnson (NYSE:JNJ) met Wall Street’s revenue expectations in Q4 CY2024, with sales up 5.3% year on year to $22.52 billion. Its non-GAAP profit of $2.04 per... 
Via StockStory
Topics Artificial Intelligence Intellectual Property
RFK Jr. And Big Pharma: Health Secretary Hopeful Answers Pointed Questions On Drugs, Insurance, Trump Exec Orders
Kennedy seeks to be Secretary of Health and Human Services — a position that would put him in charge of the health of the American people. 
Via Benzinga
Topics Government
Starbucks To Rally Over 23%? Here Are 10 Top Analyst Forecasts For Wednesday
 
Via Benzinga
Marjorie Taylor Greene Loads Up On Meta, Amazon, Tesla, Nvidia And Other Stocks As Donald Trump's New Equations With Big Tech Leaders Sets Stage For Growth: What Is At Stake?
U.S. House Representative Marjorie Taylor Greene has disclosed new trades as Donald Trump's equations evolves with Big Tech leaders. 
Via Benzinga
Topics Government
Georgia Rep. Marjorie Taylor Greene Bought Up to $45K Worth of Johnson & Johnson Stock
 
Via Benzinga
3 Stocks Upgraded by Bank of America – Here's Why They're Bullish
Bank of America analysts have recently shifted their views on these three stocks, leaving investors with a few points to consider. 
Via MarketBeat
McDonald's To Rally Around 15%? Here Are 10 Top Analyst Forecasts For Tuesday
 
Via Benzinga
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Logility Supply Chain Solutions, Inc. (Nasdaq - LGTY), Enfusion, Inc. (NYSE - ENFN), Intra-Cellular Therapies, Inc. (Nasdaq - ITCI), Shutterstock, Inc. (NYSE - SSTK)
From Brodsky & Smith LLC
Via GlobeNewswire
10 Health Care Stocks With Whale Alerts In Today's Session
 
Via Benzinga
Why Traders Are Buying the Dip on Johnson & Johnson Stock
Shares of Johnson & Johnson stock have declined by 11.5% in the quarter, and markets are calling for a bottom and rally here. 
Via MarketBeat
These Were the 5 Worst-Performing Stocks in the Dow Jones Industrial Average in 2024
Via The Motley Fool
Topics Stocks
Abbott Laboratories Will Outperform Healthcare Stocks in 2025
Johnson & Johnson and Abbott Laboratories offer substantial opportunities for investors, but one is a better buy for total returns in 2025 and 2026. 
Via MarketBeat
5 of the Safest High-Yield Dividend Stocks You Can Confidently Buy for 2025
Five magnificent income stocks -- sporting an average yield of 4.26% -- can pad investors' pocketbooks in the new year (and well beyond). 
Via The Motley Fool
Stocks Going Ex Dividend In February 2025
This article features a short list of some of the many stocks going ex-dividend during the next month, which can be helpful for traders and investors 
Via Talk Markets
Topics Stocks / Equities
Up About 62% in a Year, Can Intuitive Surgical Stock Keep Soaring?
Via The Motley Fool
Johnson & Johnson's MedTech Momentum Expected To Rebound In 2025 Despite Current Hurdles: Analyst
Analysts discuss Johnson & Johnson's outlook, highlighting MedTech challenges, litigation risks, pipeline opportunities, and mixed performance across segments. 
Via Benzinga
This Is 1 of the Healthiest High-Yielding Dividend Stocks You'll Find
Via The Motley Fool
Earnings Picture Remains Strong: A Closer Look
Total earnings for the 62 S&P 500 companies that have reported results are up +19.6% from the same period last year on +8.4% higher revenues, with 82.3% beating EPS estimates and 69.4% beating revenue... 
Via Talk Markets
Topics Stocks Stocks / Equities
S&P 500 Hits Fresh Records At 6,100: Strong Earnings, Trump's AI Wager Fuel Bull Run
Market surges on AI Stargate initiative & strong earnings. S&P 500 hits record high of 6,100 points, led by tech giants & semiconductor stocks. 
Via Benzinga
Topics Artificial Intelligence Government Stocks
Cytokinetics Heart Drug's Future Sparks Optimism Despite M&A Hurdles and Royalty Deal Concerns: Analyst
Cytokinetics receives a Buy rating from Stifel, with a promising outlook for aficamten in the $3 billion U.S. oHCM market, despite investor concerns over M&A and deals. 
Via Benzinga
Johnson & Johnson (JNJ) Q4 2024 Earnings Call Transcript
JNJ earnings call for the period ending December 31, 2024. 
Via The Motley Fool
Topics Earnings
Chipmakers Rally On AI Stargate Bet, Netflix Soars, Bitcoin Falters As Trump Keeps Quiet On Crypto: What's Driving Markets Wednesday?
Tech stocks enjoyed a surge Wednesday, driven by a sharp rise in semiconductor shares after President Donald Trump, OpenAI's Sam Altman, Oracle Corp. 
Via Benzinga
Topics Artificial Intelligence Government
< Previous 1 2
...
19 20 21 22 23 24 25 26 27
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.